Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech focused on molecular glue degrader medicines, will join two investor events. Management will participate in fireside chats at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026.
Live webcasts and 30-day archives will be available in the Events & Presentations section of the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – GLUE
In the May 20 session, GLUE gained 6.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +17.0% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
- TD Cowen 7th Annual Oncology Innovation Summit (virtual) – fireside chat, May 27, 2026, at 12:00 p.m. ET
- Jefferies Global Healthcare Conference in New York – fireside chat, June 4, 2026, at 11:40 a.m. ET
Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
